Rallybio Corporation Common Stock (RLYB)
Rallybio Corporation (RLYB) is a biotechnology company focused on developing and commercializing targeted therapies for serious genetic and rare diseases. The company primarily invests in innovative treatments aimed at addressing unmet medical needs through novel biologics and gene therapies.
Company News
Recursion Pharmaceuticals acquired full ownership of REV102, an ENPP1 inhibitor program for treating hypophosphatasia, from Rallybio, reducing pipeline uncertainty and potentially adding value to its drug development efforts.
Rallybio Corporation sold its interest in REV102, a preclinical ENPP1 inhibitor for hypophosphatasia, to Recursion Pharmaceuticals for up to $25 million, extending its cash runway into mid-2027.
RallyBio (RLYB) gains 83% after announcing a collaboration deal with J&J to develop novel therapies to reduce the risk of FNAIT in pregnant women, along with funding of $6.6 million from the latter.
Here's 3 tips for spotting penny stocks trends The post Spotting Penny Stocks Trading Trends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.